C57BL/6JCya-Fcrl5em1/Cya
Common Name
Fcrl5-KO
Product ID
S-KO-18807
Backgroud
C57BL/6JCya
Strain ID
KOCMP-329693-Fcrl5-B6J-VB
Status
When using this mouse strain in a publication, please cite “Fcrl5-KO Mouse (Catalog S-KO-18807) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Fcrl5-KO
Strain ID
KOCMP-329693-Fcrl5-B6J-VB
Gene Name
Product ID
S-KO-18807
Gene Alias
Fcrh3, mBXMH2
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 3 (Mouse)
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Transcript ID
ENSMUST00000194102
NCBI Transcript ID
NM_183222
Target Region
Exon 4~7
Size of Effective Region
~5.5 kb
Overview of Gene Research
Fcrl5, also known as FcRH5/IRTA2/CD307, is a surface protein selectively expressed on B cells and plasma cells. It plays a role in regulating B-cell function, and its expression can be influenced by different activation signals such as BCR and TLR9 activation [3].
In autoimmune diseases, Fcrl5 upregulation in B cells disrupts B cell anergy, contributing to the pathogenesis of autoimmune diseases. B cell-specific Fcrl5 transgenic mice showed systemic autoimmunity with age, and Fcrl5 upregulation exacerbated the systemic lupus erythematosus-like disease model. This indicates that Fcrl5 is a potential regulator of B cell-mediated autoimmunity [2].
In multiple myeloma, Fcrl5 is considerably upregulated. Fcrl5-directed CAR-T cells incorporating IL-15 exhibit potent antitumor efficacy, effectively inhibiting MM cell proliferation and leading to tumor suppression. Also, Fcrl5 can be a target for antibody-drug conjugates (ADCs) in multiple myeloma treatment, as Fcrl5 ADCs were efficacious in vitro and in vivo [1,4].
In conclusion, Fcrl5 is a key regulator in B-cell-related functions. Studies using transgenic mouse models have revealed its significant role in autoimmune diseases and multiple myeloma, providing potential therapeutic targets for these diseases.
References：
1. Yu, Zhengyu, Li, Hexian, Lu, Qizhong, Tong, Aiping, Niu, Ting. 2024. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma. In Signal transduction and targeted therapy, 9, 16. doi:10.1038/s41392-023-01702-2. https://pubmed.ncbi.nlm.nih.gov/38212320/
2. Ono, Chisato, Tanaka, Shinya, Myouzen, Keiko, Kochi, Yuta, Baba, Yoshihiro. 2023. Upregulated Fcrl5 disrupts B cell anergy and causes autoimmune disease. In Frontiers in immunology, 14, 1276014. doi:10.3389/fimmu.2023.1276014. https://pubmed.ncbi.nlm.nih.gov/37841260/
3. Kleberg, Linn, Courey-Ghaouzi, Alan-Dine, Lautenbach, Maximilian Julius, Färnert, Anna, Sundling, Christopher. 2024. Regulation of B-cell function and expression of CD11c, T-bet, and FcRL5 in response to different activation signals. In European journal of immunology, 54, e2350736. doi:10.1002/eji.202350736. https://pubmed.ncbi.nlm.nih.gov/38700378/
4. Elkins, Kristi, Zheng, Bing, Go, Maryann, Ebens, Allen, Polson, Andrew G. 2012. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. In Molecular cancer therapeutics, 11, 2222-32. doi:10.1158/1535-7163.MCT-12-0087. https://pubmed.ncbi.nlm.nih.gov/22807577/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
